{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:27:05Z","timestamp":1790519225916,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T00:00:00Z","timestamp":1508803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1136\/annrheumdis-2017-211682","type":"journal-article","created":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T16:20:18Z","timestamp":1508862018000},"page":"212-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":244,"title":["Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)"],"prefix":"10.1016","volume":"77","clinical-trial-number":[{"clinical-trial-number":"nct02453256","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Dinesh","family":"Khanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia J F","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy M","family":"Frech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina E","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorinda","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Fierlbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhanam","family":"Lakshminarayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Riemekasten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Steen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"M\u00fcller-Ladner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Spotswood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Jahreis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E","family":"Furst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2017-211682_bib1","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.berh.2010.10.007","article-title":"Epidemiology of systemic sclerosis","volume":"24","author":"Nikpour","year":"2010","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4 Suppl 92","key":"10.1136\/annrheumdis-2017-211682_bib2","first-page":"S3","article-title":"Systemic sclerosis: from pathogenesis to targeted therapy","volume":"33","author":"Denton","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/annrheumdis-2017-211682_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","author":"Denton","year":"2017","journal-title":"The Lancet"},{"key":"10.1136\/annrheumdis-2017-211682_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.amjmed.2004.04.031","article-title":"Mortality in systemic sclerosis: an international meta-analysis of individual patient data","volume":"118","author":"Ioannidis","year":"2005","journal-title":"Am J Med"},{"key":"10.1136\/annrheumdis-2017-211682_bib5","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2017-211682_bib6","doi-asserted-by":"crossref","first-page":"186","DOI":"10.5301\/jsrd.5000207","article-title":"Emerging strategies for treatment of systemic sclerosis","volume":"1","author":"Khanna","year":"2016","journal-title":"J Scleroderma Relat Disord"},{"issue":"2 Suppl 76","key":"10.1136\/annrheumdis-2017-211682_bib7","first-page":"122","article-title":"The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review","volume":"31","author":"Muangchant","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/annrheumdis-2017-211682_bib8","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3899\/jrheum.111423","article-title":"Interleukin 6 in systemic sclerosis and potential implications for targeted therapy","volume":"39","author":"Muangchan","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2017-211682_bib9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000163802","article-title":"In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease","volume":"61","author":"Koch","year":"1993","journal-title":"Pathobiology"},{"key":"10.1136\/annrheumdis-2017-211682_bib10","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/annrheumdis-2011-200955","article-title":"Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis","volume":"71","author":"Khan","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2017-211682_bib11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3899\/jrheum.120725","article-title":"Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis","volume":"40","author":"De Lauretis","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2017-211682_bib12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0923-1811(01)00128-1","article-title":"Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis","volume":"27","author":"Sato","year":"2001","journal-title":"J Dermatol Sci"},{"key":"10.1136\/annrheumdis-2017-211682_bib13","first-page":"275","article-title":"Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis","volume":"33","author":"Matsushita","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2017-211682_bib14","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/acr.21716","article-title":"Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group","volume":"64","author":"Muangchan","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1136\/annrheumdis-2017-211682_bib15","series-title":"Actemra (tocilizumab) injection for intravenous infusion","author":"Genentech Inc","year":"2017"},{"key":"10.1136\/annrheumdis-2017-211682_bib16","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/rheumatology\/keq275","article-title":"The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab","volume":"49","author":"Shima","year":"2010","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2017-211682_bib17","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","article-title":"Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study","volume":"72","author":"Elhai","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2017-211682_bib18","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2017-211682_bib19","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2017-211682_bib20","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/ard.2005.050187","article-title":"Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study","volume":"65","author":"Khanna","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2017-211682_bib21","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case ofbinomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1136\/annrheumdis-2017-211682_bib22","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1016\/S0140-6736(16)00622-X","article-title":"Tocilizumab for systemic sclerosis: implications for future trials","volume":"387","author":"Distler","year":"2016","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2017-211682_bib23","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/annrheumdis-2017-211682_bib24","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3899\/jrheum.120687","article-title":"Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure","volume":"40","author":"Genovese","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2017-211682_bib25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/art.22289","article-title":"Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I\/II trial of CAT-192","volume":"56","author":"Denton","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2017-211682_bib26","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/ard.2010.143974","article-title":"Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial","volume":"70","author":"Spiera","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2017-211682_bib27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1756-185X.2012.01728.x","article-title":"Incidence rate and causes of infection in Thai systemic sclerosis patients","volume":"15","author":"Foocharoen","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"10.1136\/annrheumdis-2017-211682_bib28","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3899\/jrheum.121380","article-title":"The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. a systematic review","volume":"40","author":"Muangchan","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2017-211682_bib29","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1136\/ard.2010.143420","article-title":"Reporting of long-term extension studies: lack of consistency calls for consensus","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2017-211682_bib30","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2017-211682_bib31","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/rheumatology\/keu285","article-title":"Old medications and new targeted therapies in systemic sclerosis","volume":"54","author":"Nagaraja","year":"2015","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2017-211682_bib32","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2017-211682_bib33","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2017-211682_bib34","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2017-211682_bib35","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"10.1136\/annrheumdis-2017-211682_bib36","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1182\/blood.V100.5.1602.h81702001602_1602_1610","article-title":"High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes","volume":"100","author":"McSweeney","year":"2002","journal-title":"Blood"},{"key":"10.1136\/annrheumdis-2017-211682_bib37","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2017-211682_bib38","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","article-title":"Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial","volume":"35","author":"van den Hoogen","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1136\/annrheumdis-2017-211682_bib39","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1136\/annrheumdis-2017-211682_bib40","article-title":"Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: Post-hoc analyses from the Scleroderma Lung Study I and II","author":"Namas","year":"2017","journal-title":"Arthritis Care Res"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724009968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724009968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2017-211682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:23:26Z","timestamp":1739521406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724009968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0003496724009968"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2017-211682","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2017-211682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 \u00a9 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}